Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.57 |
| ▸ | RXRB | P28702 | 1/20 | 0.57 |
| ▸ | KMO | O15229 | 1/20 | 0.55 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | FABP4 | P15090 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | DDT | P30046 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2371293 | 0.88 | KMO (0.61) | RXRARXRBKMOFABP4FOLH1 | |
| SCHEMBL2890186 | 0.82 | TSHR (0.50) | RXRARXRBFOLH1TSHR | |
| SCHEMBL10433255 | 0.82 | TPMT (0.53) | RXRARXRBBCL2L1MCL1FABP4 | |
| SCHEMBL12171377 | 0.81 | CA1 (0.53) | RXRARXRBTSHR | |
| SCHEMBL30259065 | 0.81 | KMO (0.73) | RXRARXRBKMOFOLH1DDT | |
| SCHEMBL2213546 | 0.81 | KMO (0.73) | RXRARXRBKMOFOLH1DDT | |
| SCHEMBL8443917 | 0.81 | KMT2A (0.52) | BCL2L1MCL1CYP2C9 | |
| SCHEMBL6254589 | 0.81 | RXRA (0.59) | RXRARXRBKMOFOLH1DDT | |
| SCHEMBL5567627 | 0.80 | RXRA (0.54) | RXRARXRBKMOFOLH1DDT | |
| SCHEMBL1707626 | 0.80 | KMO (0.70) | RXRARXRBKMOFOLH1DDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | disclosed |
| US-20040198780-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-10-07 | — | — | US | disclosed |
| US-5968985-A | INHIBITORS OF SODIUM ION/HYDROGEN ION EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-19 | — | — | US | disclosed |
| EP-0773927-A2 | BENZOYLGUANIDINE DERIVATIVES AS MEDICAMENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996004241-A2 | BENZOYLGUANIDINE DERIVATIVES AS MEDICAMENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198780-A1 | Inhibitors of cathepsin S | CTSS, CTSK, CTSE | RXRA 4851/4885RXRB 4839/4885KMO 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.